All In Biotech

Drug Trial Radar · NCT06664801

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept (MK-7962) Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care

Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

164

Actual

Start

Nov 14, 2024

Primary completion

Nov 20, 2025

Study completion Nov 20, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. The goal of the study is to learn: * What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this trial. * About the safety of sotatercept and if people tolerate it

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • SotaterceptBiological

    SC administered every 3 weeks.

  • Background PAH TherapyBiological

    Background PAH therapy may consist of the following drug classes: single, double, or triple combination of therapy with endothelin-receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogs or receptor antagonists

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Steady-State Average Serum Concentrations of Sotatercept (Cavg)Time frame: Predose and at designated time points post-dose (up to 24 weeks)
  2. Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to 37 weeks
  3. Number of Participants who Discontinue Study Treatment due to an Adverse EventTime frame: Up to 21 weeks

Locations

98 sites in 21 countries. Site status is shown where the registry gives one.

  • Pulmonary Associates, PA ( Site 1903)

    Phoenix, Arizona

  • University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 1930)

    Aurora, Colorado

  • Indiana University Health Methodist Hospital ( Site 1905)

    Indianapolis, Indiana

  • University of Kansas Medical Center ( Site 1928)

    Kansas City, Kansas

  • Norton Pulmonary Specialists ( Site 1935)

    Louisville, Kentucky

  • University of New Mexico Health Sciences Center - Department of Internal Medicine ( Site 1916)

    Albuquerque, New Mexico

  • University of Cincinnati Medical Center ( Site 1927)

    Cincinnati, Ohio

  • Ascension Seton Heart Specialty Care and Transplant Center ( Site 1918)

    Austin, Texas

  • Froedtert Hospital & the Medical College of Wisconsin ( Site 1934)

    Milwaukee, Wisconsin

  • Hospital Britanico de Buenos Aires ( Site 0004)

    CABA, Argentina

  • Instituto de Cardiologia Juana F. Cabral ( Site 0008)

    Corrientes, Argentina

  • Hospital Provincial Jose Maria Cullen ( Site 0005)

    Santa Fe, Argentina

  • Centro Medico Capital ( Site 0002)

    La Plata, Buenos Aires, Argentina

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0006)

    Mar del Plata, Buenos Aires, Argentina

  • Instituto Medico Rio Cuarto ( Site 0010)

    Río Cuarto, Córdoba Province, Argentina

  • Royal Prince Alfred Hospital ( Site 0103)

    Camperdown, New South Wales, Australia

  • Westmead Hospital ( Site 0100)

    Westmead, New South Wales, Australia

  • Wesley Research Institute ( Site 0101)

    Auchenflower, Queensland, Australia

  • The Alfred Hospital ( Site 0102)

    Melbourne, Victoria, Australia

  • Peter Lougheed Centre ( Site 0203)

    Calgary, Alberta, Canada

  • IUCPQ ( Site 0208)

    Québec, Quebec, Canada

  • Guangdong Provincial People s Hospital ( Site 2000)

    Guangzhou, Guangdong, China

  • The Second Xiangya Hospital of Central South University ( Site 2002)

    Changsha, Hunan, China

  • Shanghai Pulmonary Hospital ( Site 2004)

    Shanghai, Shanghai Municipality, China

  • Yan an Hospital of Kunming City ( Site 2011)

    Kunming, Yunnan, China

  • Clinica Cardio VID ( Site 0307)

    Medellín, Antioquia, Colombia

  • Clinica Colsanitas - Sede Reina Sofia ( Site 0303)

    Bogotá, Bogota D.C., Colombia

  • Fundacion Santa Fe de Bogota ( Site 0302)

    Bogota, Cundinamarca, Colombia

  • IMAT S.A.S ( Site 0301)

    Montería, Departamento de Córdoba, Colombia

  • Centro de Investigaciones Clinicas SAS ( Site 0306)

    Cali, Valle del Cauca Department, Colombia

  • Clínica Imbanaco S.A.S ( Site 0304)

    Cali, Valle del Cauca Department, Colombia

  • Centrum pro plicní hypertenzi VFN II. interni klinika VFN a 1. LF UK ( Site 0400)

    Prague, Praha 2, Czechia

  • CHU Bordeaux Haut-Leveque ( Site 0501)

    Pessac, Aquitaine, France

  • Assistance Publique Hôpitaux de Marseille - Hôpital Nord ( Site 0500)

    Marseille, Bouches-du-Rhone, France

  • CHU Dijon Bourgogne ( Site 0502)

    Dijon, Cote-d Or, France

  • CHU de Rouen ( Site 0503)

    Rouen, Haute-Normandie, France

  • CHU GABRIEL MONTPIED ( Site 0504)

    Clermont-Ferrand, Puy-de-Dome, France

  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0609)

    Berlin, Germany

  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0610)

    Hamburg, Germany

  • Thoraxklinik-Heidelberg gGmbH-Zentrum für Pulmonale Hypertonie ( Site 0600)

    Heidelberg, Baden-Wurttemberg, Germany

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.